{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:38:58Z","timestamp":1781800738074,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00259-022-06047-6","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T07:03:12Z","timestamp":1669186992000},"page":"1240-1251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET\/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study"],"prefix":"10.1007","volume":"50","author":[{"given":"Zhi-Bin","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Bo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong-Lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Shui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Yi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-7025","authenticated-orcid":false,"given":"Ning","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"6047_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654.","journal-title":"CA Cancer J Clin"},{"key":"6047_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","volume":"11","author":"AJ Chang","year":"2014","unstructured":"Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11:308\u201323. https:\/\/doi.org\/10.1038\/nrclinonc.2014.68.","journal-title":"Nat Rev Clin Oncol"},{"key":"6047_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.urolonc.2019.07.009","volume":"37","author":"J Pan","year":"2019","unstructured":"Pan J, Chi C, Qian H, Zhu Y, Shao X, Sha J, et al. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: a retrospective comparative study. Urol Oncol. 2019;37:991\u20138. https:\/\/doi.org\/10.1016\/j.urolonc.2019.07.009.","journal-title":"Urol Oncol"},{"key":"6047_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1756-8722-7-20","volume":"7","author":"M Thalgott","year":"2014","unstructured":"Thalgott M, Horn T, Heck MM, Maurer T, Eiber M, Retz M, et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. J Hematol Oncol. 2014;7:20. https:\/\/doi.org\/10.1186\/1756-8722-7-20.","journal-title":"J Hematol Oncol"},{"key":"6047_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4103\/aja.aja_96_20","volume":"23","author":"W Liu","year":"2021","unstructured":"Liu W, Yao Y, Liu X, Liu Y, Zhang GM. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2021;23:429\u201336. https:\/\/doi.org\/10.4103\/aja.aja_96_20.","journal-title":"Asian J Androl"},{"key":"6047_CR6","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/jco.20.00315","volume":"38","author":"JA Eastham","year":"2020","unstructured":"Eastham JA, Heller G, Halabi S, Monk JP 3rd, Beltran H, Gleave M, et al. Cancer and leukemia group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer. J Clin Oncol. 2020;38:3042\u201350. https:\/\/doi.org\/10.1200\/jco.20.00315.","journal-title":"J Clin Oncol"},{"key":"6047_CR7","first-page":"949","volume":"18","author":"M Dolezel","year":"2013","unstructured":"Dolezel M, Odrazka K, Vanasek J, Vaculikova M, Vlkova-Sefrova J, Jansa J, et al. Neoadjuvant hormonal therapy in prostate cancer - impact of PSA level before radiotherapy. J Buon. 2013;18:949\u201353.","journal-title":"J Buon"},{"key":"6047_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.119.234187","volume":"61","author":"J Kuten","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-head comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020;61:527\u201332. https:\/\/doi.org\/10.2967\/jnumed.119.234187.","journal-title":"J Nucl Med"},{"key":"6047_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/s0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"6047_CR10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2967\/jnumed.119.237602","volume":"61","author":"I Sonni","year":"2020","unstructured":"Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, et al. Impact of (68)Ga-PSMA-11 PET\/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study. J Nucl Med. 2020;61:1153\u201360. https:\/\/doi.org\/10.2967\/jnumed.119.237602.","journal-title":"J Nucl Med"},{"key":"6047_CR11","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2967\/jnumed.119.226381","volume":"60","author":"E Rousseau","year":"2019","unstructured":"Rousseau E, Wilson D, Lacroix-Poisson F, Krauze A, Chi K, Gleave M, et al. A prospective study on (18)F-DCFPyL PSMA PET\/CT imaging in biochemical recurrence of prostate cancer. J Nucl Med. 2019;60:1587\u201393. https:\/\/doi.org\/10.2967\/jnumed.119.226381.","journal-title":"J Nucl Med"},{"key":"6047_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/bju.14944","volume":"125","author":"HB Luiting","year":"2020","unstructured":"Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, et al. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU Int. 2020;125:206\u201314. https:\/\/doi.org\/10.1111\/bju.14944.","journal-title":"BJU Int"},{"key":"6047_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","volume":"48","author":"S Fanti","year":"2021","unstructured":"Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, et al. Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:469\u201376. https:\/\/doi.org\/10.1007\/s00259-020-04934-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6047_CR14","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324. https:\/\/doi.org\/10.1007\/s00259-017-3670-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6047_CR15","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s12149-021-01610-x","volume":"35","author":"D Has Simsek","year":"2021","unstructured":"Has Simsek D, Kuyumcu S, Karadogan S, Oflas M, Isik EG, Ozkan ZG, et al. Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer? Ann Nucl Med. 2021;35:680\u201390. https:\/\/doi.org\/10.1007\/s12149-021-01610-x.","journal-title":"Ann Nucl Med"},{"key":"6047_CR16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s12149-019-01387-0","volume":"33","author":"C Schmidkonz","year":"2019","unstructured":"Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, et al. 68Ga-PSMA-11 PET\/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Ann Nucl Med. 2019;33:766\u201375. https:\/\/doi.org\/10.1007\/s12149-019-01387-0.","journal-title":"Ann Nucl Med"},{"key":"6047_CR17","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1097\/mnm.0000000000001459","volume":"42","author":"B Okudan","year":"2021","unstructured":"Okudan B, Co\u015fkun N, Seven B, Atalay MA, Yildirim A, G\u00f6rtan FA. Assessment of volumetric parameters derived from 68Ga-PSMA PET\/CT in prostate cancer patients with biochemical recurrence: an institutional experience. Nucl Med Commun. 2021;42:1254\u201360. https:\/\/doi.org\/10.1097\/mnm.0000000000001459.","journal-title":"Nucl Med Commun"},{"key":"6047_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59:469\u201378. https:\/\/doi.org\/10.2967\/jnumed.117.198119.","journal-title":"J Nucl Med"},{"key":"6047_CR19","doi-asserted-by":"publisher","unstructured":"Kayal EB, Alampally JT, Sharma R, Bakhshi S, Mehndiratta A, Kumar R, et al. Chemotherapy response evaluation using diffusion weighted MRI in Ewing sarcoma: a single center experience. Acta radiologica (Stockholm, Sweden : 1987). 2022:2841851221124669. https:\/\/doi.org\/10.1177\/02841851221124669.","DOI":"10.1177\/02841851221124669"},{"key":"6047_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.18999\/nagjms.80.2.183","volume":"80","author":"K Kitajima","year":"2018","unstructured":"Kitajima K, Miyoshi Y, Yamano T, Odawara S, Higuchi T, Yamakado K. Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET\/CT-RECIST 1.1 vs. PERCIST 1.0. Nagoya J Med Sci. 2018;80:183\u201397. https:\/\/doi.org\/10.18999\/nagjms.80.2.183.","journal-title":"Nagoya J Med Sci"},{"key":"6047_CR21","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/s1470-2045(21)00376-4","volume":"22","author":"JS de Bono","year":"2021","unstructured":"de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol. 2021;22:1250\u201364. https:\/\/doi.org\/10.1016\/s1470-2045(21)00376-4.","journal-title":"Lancet Oncol"},{"key":"6047_CR22","doi-asserted-by":"publisher","unstructured":"O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology 2016;280:576-584. https:\/\/doi.org\/10.1148\/radiol.2016142043.","DOI":"10.1148\/radiol.2016142043"},{"key":"6047_CR23","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.7150\/thno.39838","volume":"10","author":"EM Velez","year":"2020","unstructured":"Velez EM, Desai B, Ji L, Quinn DI, Colletti PM, Jadvar H. Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. Theranostics. 2020;10:3254\u201362. https:\/\/doi.org\/10.7150\/thno.39838.","journal-title":"Theranostics"},{"key":"6047_CR24","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/ju.0000000000001481","volume":"205","author":"M Chen","year":"2021","unstructured":"Chen M, Zhuang J, Fu Y, Guo S, Zang S, Ai S, et al. Can (68)Ga-PSMA-11 positron emission tomography\/computerized tomography predict pathological response of primary prostate cancer to neoadjuvant androgen deprivation therapy? A pilot study. J Urol. 2021;205:1082\u20139. https:\/\/doi.org\/10.1097\/ju.0000000000001481.","journal-title":"J Urol"},{"key":"6047_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/ppo.0000000000000424","volume":"26","author":"ST Ryan","year":"2020","unstructured":"Ryan ST, Patel DN, Parsons JK, McKay RR. Neoadjuvant approaches prior to radical prostatectomy. Cancer J (Sudbury, Mass). 2020;26:2\u201312. https:\/\/doi.org\/10.1097\/ppo.0000000000000424.","journal-title":"Cancer J (Sudbury, Mass)"},{"key":"6047_CR26","first-page":"251","volume":"4","author":"FM Debruyne","year":"2000","unstructured":"Debruyne FM, Witjes WP. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. Mol Urol. 2000;4:251\u20136 discussion 7.","journal-title":"Mol Urol"},{"key":"6047_CR27","doi-asserted-by":"publisher","first-page":"386809","DOI":"10.1155\/2013\/386809","volume":"2013","author":"S Sfoungaristos","year":"2013","unstructured":"Sfoungaristos S, Kourmpetis V, Fokaefs E, Perimenis P. Neoadjuvant chemotherapy prior to radical prostatectomy for patients with high-risk prostate cancer: a systematic review. Chemother Res Pract. 2013;2013:386809. https:\/\/doi.org\/10.1155\/2013\/386809.","journal-title":"Chemother Res Pract"},{"key":"6047_CR28","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/ju.0000000000001632","volume":"205","author":"RR McKay","year":"2021","unstructured":"McKay RR, Berchuck J, Kwak L, Xie W, Silver R, Bubley GJ, et al. Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials. J Urol. 2021;205:1689\u201397. https:\/\/doi.org\/10.1097\/ju.0000000000001632.","journal-title":"J Urol"},{"key":"6047_CR29","doi-asserted-by":"publisher","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-update and clarification: from the RECIST committee. European journal of cancer (Oxford, England : 1990). 2016;62:132-137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081.","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"6047_CR30","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaoncol.2018.2168","volume":"4","author":"KA Autio","year":"2018","unstructured":"Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, et al. Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial. JAMA Oncol. 2018;4:1344\u201351. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2168.","journal-title":"JAMA Oncol"},{"key":"6047_CR31","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/jco.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510\u20137. https:\/\/doi.org\/10.1200\/jco.2015.64.0391.","journal-title":"J Clin Oncol"},{"key":"6047_CR32","doi-asserted-by":"publisher","unstructured":"Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardi\u00e8re C, Tougeron D, et al. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. J Immunother Cancer. 2020:8. https:\/\/doi.org\/10.1136\/jitc-2020-001499.","DOI":"10.1136\/jitc-2020-001499"},{"key":"6047_CR33","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/j.ejrad.2010.07.023","volume":"80","author":"C Fuccio","year":"2011","unstructured":"Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET\/CT for prostate cancer: main clinical applications. Eur J Radiol. 2011;80:e50\u20136. https:\/\/doi.org\/10.1016\/j.ejrad.2010.07.023.","journal-title":"Eur J Radiol"},{"key":"6047_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40364-021-00306-8","volume":"9","author":"CC Ko","year":"2021","unstructured":"Ko CC, Yeh LR, Kuo YT, Chen JH. Imaging biomarkers for evaluating tumor response: RECIST and beyond. Biomark Res. 2021;9:52. https:\/\/doi.org\/10.1186\/s40364-021-00306-8.","journal-title":"Biomark Res"},{"key":"6047_CR35","doi-asserted-by":"publisher","unstructured":"Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, Gwyther S, et al. Evaluation of lymph nodes with RECIST 1.1. European journal of cancer, vol. 45. (Oxford, England; 1990, 2009. p. 261\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.028.","DOI":"10.1016\/j.ejca.2008.10.028"},{"key":"6047_CR36","doi-asserted-by":"publisher","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer, vol. 45. (Oxford, England; 1990, 2009. p. 228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"6047_CR37","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1515\/cclm-2014-0988","volume":"53","author":"X Filella","year":"2015","unstructured":"Filella X, Foj L. Emerging biomarkers in the detection and prognosis of prostate cancer. Clin Chem Lab Med. 2015;53:963\u201373. https:\/\/doi.org\/10.1515\/cclm-2014-0988.","journal-title":"Clin Chem Lab Med"},{"key":"6047_CR38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2967\/jnumed.117.195172","volume":"59","author":"N Woythal","year":"2018","unstructured":"Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K, et al. Immunohistochemical validation of PSMA EXPRESSION MEASURED by (68)Ga-PSMA PET\/CT in primary prostate cancer. J Nucl Med. 2018;59:238\u201343. https:\/\/doi.org\/10.2967\/jnumed.117.195172.","journal-title":"J Nucl Med"},{"key":"6047_CR39","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/mnm.0000000000000942","volume":"40","author":"E Demirci","year":"2019","unstructured":"Demirci E, Kabasakal L, \u015eahin OE, Akg\u00fcn E, G\u00fcltekin MH, Do\u011fanca T, et al. Can SUVmax values of Ga-68-PSMA PET\/CT scan predict the clinically significant prostate cancer? Nucl Med Commun. 2019;40:86\u201391. https:\/\/doi.org\/10.1097\/mnm.0000000000000942.","journal-title":"Nucl Med Commun"},{"key":"6047_CR40","doi-asserted-by":"publisher","unstructured":"Xue AL, Kalapara AA, Ballok ZE, Levy SM, Sivaratnam D, Ryan A, et al. (68)Ga-prostate-specific membrane antigen positron emission tomography maximum standardized uptake value as a predictor of Gleason pattern 4 and pathological upgrading in intermediate-risk prostate cancer. J Urol. 2021:101097ju0000000000002254. https:\/\/doi.org\/10.1097\/ju.0000000000002254.","DOI":"10.1097\/ju.0000000000002254"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06047-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-06047-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06047-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T03:04:41Z","timestamp":1676516681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-06047-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["6047"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-06047-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University (Approved No. of ethic committee: MRCTA, ECFAH of FMU [2021]208), and all patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors read the final manuscript and agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}